Retatrutide is a biologically derived peptide and, like other authorised incretin-based injectable medicines, is expected to be sensitive to temperature fluctuations, light exposure, and physical agitation
for example, Lilly expects to share Phase 3 obesity data on orfoglipron, an oral GLP-1 agonist, and retatrutide, a triple agonist of GLP/GIP/glucagon receptors in 2025 3 Xie, Y., Choi, T., & Al-Aly, Z
To exclude artifactual alterations by the FITC group, we performed kinetic-binding experiments with unlabeled agonists, in competition with exendin-4-FITC, and defined both association rate constants and residence times 43 with consistent effects (Fig
Further investigation could lead to new treatments for chronic conditions
Mild fluid retention some patients experience mild water retention, particularly in the first 2 to 4 weeks